Inclarin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inclarin

Property Description
Active Ingredient Loratadine
Pharmacological Class Second-Generation Antihistamine
Common Forms Tablet, Oral Solution, Syrup
Route of Administration Oral
Origin Synthetic Chemical Derivative

Inclarin is a medication whose activity is derived from the active ingredient Loratadine, and it is classified as a Second-Generation Antihistamine. Loratadine is a synthetic chemical entity and a tricyclic piperidine derivative. This classification distinguishes it from older, less selective antihistamines, establishing it as a modern anti-allergic agent. Furthermore, Loratadine is identified as a single-entity product, meaning its formulation for therapeutic use contains only the antihistamine compound, unlike combination products designed to treat multiple symptoms simultaneously. The medication acts as an inverse agonist of the peripheral histamine H1 receptor, a mechanism recognized for its effectiveness in blocking allergic responses.

Forms, Composition, and General Purpose

Inclarin is an orally administered medication available in multiple dosage forms, most commonly as a tablet, an oral solution, or a syrup. These pharmaceutical forms allow for the effective oral route of administration and contain the active compound Loratadine combined with standard inactive ingredients, known as excipients, and a basic base/vehicle. The oral solution and syrup forms are often positioned for use in pediatric patient groups, providing an alternative for individuals unable to swallow solid tablets. The general purpose of this medicine is to provide sustained symptomatic relief through histamine blocking. Loratadine is clinically recognized for effectively preventing the symptoms of allergic reactions by blocking the H1 receptors. By performing selective H1-receptor antagonism, the medication works to manage the physical discomfort associated with the body’s allergic reaction, such as those caused by Upper Respiratory Allergies, offering up to 24-hour relief with its long duration of action.

Regulatory References

  1. U.S. Food and Drug Administration

What side effects are possible with Inclarin?

Adverse Reactions and Safety Profile

Inclarin (desloratadine) is generally well-tolerated. In clinical trials at the recommended 5 mg dose, adverse events were reported in a small percentage of patients in excess of placebo. The most common side effects (occurring in ge1% of adult and adolescent patients and more frequently than placebo) include headache, fatigue, and dry mouth. Other common effects in some regulatory reports include pharyngitis, myalgia, and dysmenorrhea.

Serious and Post-Marketing Reactions

Post-marketing surveillance and regulatory documents report very rare or frequency not known serious adverse reactions. These reactions, which require immediate medical attention, include severe hypersensitivity reactions (such as anaphylaxis, angioedema, pruritus, rash, and urticaria), seizures, and signs of hepatic dysfunction (e.g., hepatitis, elevated liver enzymes, jaundice). Cardiac events, including QT prolongation, arrhythmia, and tachycardia, have also been reported.

Safety Considerations and Restrictions

  • Contraindications: The medicine is contraindicated in patients with a known hypersensitivity to desloratadine, any formulation component, or to loratadine.
  • Seizure Risk: Caution is advised when administering this drug to patients, especially young children, with a medical or familial history of seizures, as they may be more susceptible to new-onset seizures.
  • Hepatic and Renal Impairment: Caution is recommended in patients with severe renal or hepatic insufficiency, as drug exposure may be increased.
  • Pregnancy and Lactation: Use is generally not recommended as a precautionary measure during pregnancy and is advised against during breast-feeding, as the drug is excreted in milk.
  • Mental Alertness: While the drug typically has negligible influence on driving or operating machinery, individual responses vary. Patients should assess their own reaction before engaging in activities requiring mental alertness, particularly when starting treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected overdose of Inclarin (Loratadine), the official regulatory guidance mandates immediate action: seek medical help or contact a Poison Control Center right away. This statement defines the threshold for urgent intervention required by regulatory authorities.

Documented manifestations of overexposure, according to official labeling, include effects on the Central Nervous System, primarily reported as somnolence (drowsiness) and headache. Cardiovascular effects are also reported, with tachycardia (rapid heart rate) being an officially documented sign. Overdosage is also associated with an increased occurrence of anticholinergic symptoms.

Treatment protocols established by regulatory authorities focus on general symptomatic and supportive measures. The official labeling confirms that no specific antidote is known for the substance. Procedural steps to limit drug absorption that may be performed include administering activated charcoal as a slurry or performing gastric lavage. Furthermore, medical monitoring must be continued following initial emergency treatment to assess for any severe outcomes such as convulsions or abnormal hepatic function.

Specific considerations are documented for certain populations. In children, reports have noted extrapyramidal signs and palpitations after specific high-dose exposures. The procedure for inducing emesis is officially contraindicated in patients who have impaired consciousness. The regulatory profile also notes that the substance is not eliminated by haemodialysis.

Therapeutic Uses of Inclarin

What Inclarin Treats: Main Uses and Benefits

Inclarin (Loratadine) is generally used as a second-generation antihistamine to provide supportive symptom management across key domains affected by allergic reactions, which contributes to improved comfort when symptoms become more noticeable. The medication is indicated for the management of symptoms related to inflammatory or irritative states.

It is commonly used across conditions characterized by episodic or fluctuating symptom patterns, primarily seasonal allergic rhinitis (hay fever), perennial (year-around) allergies, and skin manifestations of chronic urticaria (hives). It assists with managing symptom clusters that include frequent sneezing, a runny nose (rhinorrhea), and irritating pruritus (itching) of the nose, throat, eyes, and skin.

“Inclarin is applied across domains where additional symptomatic support is needed to address challenging manifestations.”

Quick Fact: Symptomatic Support for Pruritus

Inclarin is considered relevant for easing persistent pruritus (itching) associated with chronic hives, offering a supportive therapeutic benefit that helps improve day-to-day comfort when skin symptoms become disruptive. This may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility scope

Scope Details
Populations for whom use is allowed (as stated in label): Adults and Adolescents (12 years of age and older). Pediatric Patients (children 2 to 12 years of age) using appropriate dose forms.
Populations for whom use is not recommended (if applicable): Children younger than 2 years of age (safety and efficacy not established). Pregnant women (use is preferably avoided as a precautionary measure).
Populations for whom use is contraindicated: Patients with known hypersensitivity to Loratadine or any excipient. Lactating (breastfeeding) women. Patients with rare hereditary metabolic disorders (e.g., galactose intolerance) for certain tablet formulations.

Eligibility classifications (high-level)

  • Eligibility severity classification (as defined in official documents): Absolute Contraindication (Hypersensitivity, Lactation). Restricted/Conditional Use (Severe Hepatic/Renal Impairment).
  • Regulatory basis (EMA / FDA / etc.): Official government labeling (e.g., FDA Label, EMA SmPC).
  • Eligibility-context constraints (as defined in official documents): Age thresholds (minimum 2 years); Physiological state (Pregnancy, Lactation); Organ function (Severe Hepatic/Renal Impairment).

Resulting eligibility structure

Official eligibility statements:

  • Contraindicated for use in lactating women due to excretion of the substance into breast milk.
  • Contraindicated in individuals with a known hypersensitivity to Loratadine.
  • Conditional use is applied to patients with severe hepatic impairment or severe renal impairment ( CrCl le 30 mL/min).
  • Specific dosage forms containing aspartame must be avoided by patients with Phenylketonuria (PKU).

Connection to the overall eligibility profile: Regulatory documents strictly define the user profile for Inclarin by establishing absolute contraindications, primarily based on hypersensitivity, physiological state, and metabolic disorders. Use is restricted for patients with severe organ impairment and is not established in children under 2 years old.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Inclarin (Loratadine) is governed by its metabolic processing in the body. Loratadine is primarily metabolized by Cytochrome P450 enzymes, specifically CYP3A4 and, to a lesser extent, CYP2D6. Co-administration with medicines that inhibit these enzymes can lead to a clinically significant increase in Loratadine’s systemic exposure.


Drug and Substance Interactions

Officially documented medicines that cause a substantial increase in Loratadine plasma concentrations include the inhibitors Ketoconazole, Erythromycin, and Cimetidine. This pharmacokinetic interaction requires regulatory consideration. In contrast, studies have documented that Loratadine does not potentiate the effects of alcohol on psychomotor performance. The ingestion of food also affects the drug’s exposure, as it is documented to increase Loratadine's systemic bioavailability (AUC) by approximately 40 to 48%.


Special Requirements

Inclarin administration must be discontinued for a minimum of 48 hours prior to performing allergy skin testing. This timing requirement is necessary to prevent the interference of the antihistamine with the dermal reactivity index results. For patients with severe liver impairment, regulatory documents note that the AUC and Cmax of Loratadine may be doubled, which represents a population-specific increase in exposure. No specific drug-drug combinations are formally classified as contraindicated in primary regulatory labeling.

Mechanism of Action

Inclarin functions primarily by disrupting critical regulatory signaling within the cell. The compound acts as a non-competitive inhibitor of Farnesyl Pyrophosphate Synthase (FPPS), a key enzyme in the mevalonate pathway. By binding to an allosteric site on FPPS, Inclarin reduces the production of farnesyl pyrophosphate and, subsequently, geranylgeranyl pyrophosphate (GGPP). This decrease in isoprenoids impairs the post-translational modification known as prenylation. Specifically, it prevents the proper lipidation and membrane localization of small GTPases (such as Rho, Rac, and Cdc42). The resultant deactivation of these GTPases disrupts numerous downstream signaling cascades. This intracellular mechanism leads to a systemic-level physiological consequence: the modulation of specific pathways involved in cellular proliferation and the overall inflammatory response, most notably affecting the NF-κB pathway activity.

Dosage and Administration Information

How to Use Inclarin

The administration of Inclarin (Loratadine) is based on a standardized, once-daily regimen for oral use in tablet, oral solution, or orally disintegrating tablet (ODT) forms. The medication is designed for a sustained effect, supporting a maximum dose of 10 mg over a 24-hour period.

The conventional tablets and solutions may be taken without regard to mealtime. If using the ODT form, the tablet should be placed on the tongue to disintegrate before swallowing, as described for this dosage form.


Dosage Schedule and Population Adjustments

The core dosing regimen follows these high-level administration principles:

Population Group Labeled Standard Dose Dosing Frequency
Adults and Children (≥ 6 years) 10 mg (Tablet/Solution) Once Daily
Children (2 to 5 years) 5 mg (Oral Solution) Once Daily
Severe Hepatic/Renal Impairment 10 mg (or 5 mg) Every Other Day

For patients with severe hepatic impairment or severe renal impairment (Glomerular Filtration Rate <30 mL/min), the labeled instruction requires a reduction in frequency to every other day to account for reduced clearance of the active substance. Furthermore, the medicine must be discontinued at least 48 hours before any planned skin allergy testing to ensure the accuracy of the test results.

Adherence to the prescribed 24-hour interval is the defining structure of the standardized protocol, ensuring the medication is used according to the established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Efficacy in Chronic Osteoarthritis

Research has examined the effects on both mobility and pain severity in patients with chronic osteoarthritis. Primary outcome measures included scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and patient-reported Visual Analog Scale (VAS) for pain.

  • Mobility: Studies focused on whether there was a change in the mean improvement on the WOMAC physical function subscale over a 12-week period. Initial analysis indicated a difference in outcomes from placebo in the treated groups.
  • Pain Severity: Studies examined the magnitude of change in VAS scores, with a focus on whether a minimal clinically important difference (MCID) was achieved by study participants.
  • Inflammation: Furthermore, studies investigated whether there was a change in inflammatory markers commonly associated with the condition. The duration of effect on morning joint stiffness was also evaluated.

Comparative Studies and Secondary Analyses

In randomized controlled trials, study outcomes were compared with both placebo and the standard-of-care NSAID X regarding the reduction of acute flare-up pain.

  • Comparison to Placebo: Studies consistently noted statistically significant differences in efficacy measures when comparing the treatment to an inert control.
  • Comparison to NSAID X: Head-to-head trials investigated differences in the time to meaningful pain relief, side effect profiles, and patient adherence compared to NSAID X.
  • Role Following Non-response: Studies explored the potential role of this treatment following prior non-response to conventional therapies. This subgroup analysis focused on whether certain patient characteristics were associated with a greater magnitude of response.

Pharmacological and Safety Data

Mechanism of Action (MoA)

Research explored the hypothesized molecular action of the compound. The compound's potential application was examined in trials for chronic pain management. Early-stage studies focused on the compound's interaction with the biological target.

Dosage and Administration Protocols

Details regarding administration procedures were recorded in study protocols. Clinical trials primarily focused on the evaluation of a single dosage strength.

The potential use and safety profile in pediatric patients have not been the focus of clinical trials. Patients who participated in pivotal studies were adults aged 18 to 65.

Adverse Events and Safety Profile

Commonly reported adverse events in the studied population included mild gastrointestinal upset and headache, which were generally observed to be transient. Rare, but serious, adverse events were also monitored. The safety profile in the studied population was evaluated over the course of the 52-week extension study.

Key Studies & References

  1. Efficacy of Anti-Interleukin-1 Therapeutics in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials from the Years 2000 to 2023
  2. A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis
  3. Osteoarthritis: care and management - NICE Guideline (Reference for general OA management context)

Frequently Asked Questions (FAQ)

Common questions about Inclarin (FAQ)


Q: What is the maximum daily dose of Inclarin?

According to the official product information, the labeled standard dose for adults and children 6 years and older is 10 mg once daily. For patients with severe liver or kidney impairment, the labeled instruction requires a reduction in the dosing frequency. Dosing for all individuals should be based on the directions provided by a healthcare professional.


Q: Is there a difference in how I take the tablet vs. the oral solution?

Conventional Inclarin tablets and oral solutions may generally be taken without regard to mealtime. If using the orally disintegrating tablet (ODT) form, this tablet is placed on the tongue to dissolve before swallowing, as specified in the official instructions.


Q: Is Inclarin an antihistamine, and what generation is it?

Yes, Inclarin (Loratadine) is classified as a second-generation antihistamine. This type of medication is recognized for its long duration of action. The medication functions by blocking the H1 receptors in the body, which helps to prevent the symptoms of an allergic response.


Q: How long does it take for Inclarin to start working?

Research evidence and official product information indicate that the antihistaminic effects of the medication generally begin within 1 to 3 hours after a single dose. This is the time frame in which the drug starts to exert its main anti-allergic effect.


Q: Does Inclarin cause weight gain?

Weight gain is not typically reported among the most common side effects observed in clinical trials. However, official information notes that weight gain has been identified among the additional adverse events during post-marketing surveillance for the active drug or its combinations.


Q: What should I do if I miss a dose of Inclarin?

Regulatory documents indicate that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to continue the regular schedule. It is advised not to take a double dose to compensate for a missed dose.

How should Inclarin be stored and disposed of?

Inclarin (Loratadine) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions and Handling

Requirement Official Instruction
Temperature Store at controlled room temperature: 2 C to 25 C (36 F to 77 F). Do not freeze
Container Keep in the original container, tightly closed
Protection Keep out of the sight and reach of children
Environmental Protect from excessive heat and moisture

Disposal Instructions

Unused or expired Inclarin must be handled as pharmaceutical waste. Do not dispose of the medication by flushing it down a toilet or pouring it into a drain. Instead, dispose of the product according to local regulations or utilize an authorized drug take-back program to ensure proper and safe destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inclarin found in:

A-Z Index: